A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines

Kendric Wang1, Raunak Shrestha2, Alexander W Wyatt1

  • 1Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, Canada.

Plos One
|July 19, 2014
PubMed

Insights

This study reveals new pan-cancer drug resistance mechanisms by analyzing cell line data. Findings identify key markers for DNA repair, interferon/STAT-1 pathways, and MEK signaling, advancing precision oncology.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Cancer Cell Biology

Background:

  • Precision oncology requires understanding heterogeneous cancer drug responses.
  • Genomic analyses identified some resistance mechanisms like MDR genes and target mutations, but these explain only a fraction of patient outcomes.
  • Additional mechanisms are needed to fully explain diverse patient responses to cancer therapies.

Purpose of the Study:

  • To conduct a pan-cancer analysis of in vitro drug sensitivities across diverse cancer lineages.
  • To identify robust and recurrent determinants of drug response using a novel statistical framework.
  • To uncover known and novel mechanisms of resistance and sensitivity to cytotoxic and targeted cancer therapies.

Main Methods:

  • Developed a statistical framework based on meta-analysis of expression profiles.
  • Utilized the Cancer Cell Line Encyclopaedia (CCLE) dataset comprising hundreds of cancer cell lines.
  • Characterized response mechanisms to Topoisomerase 1 (TOP1) inhibitors, histone deacetylase (HDAC) inhibitors, and MAP/ERK kinase (MEK) inhibitors.

Main Results:

  • Identified reduced replication/transcription rates and DNA damage repair deficiencies as resistance mechanisms to TOP1 inhibitors.
  • Linked constitutive activation of interferon/STAT-1 pathways to resistance against pan-HDAC inhibitors.
  • Discovered upstream MEK dysregulations as compensatory resistance mechanisms to MEK inhibitors.

Conclusions:

  • The pan-cancer meta-analysis approach effectively elucidates drug response mechanisms.
  • The identified markers and mechanisms provide a foundation for future research in cancer drug response.
  • This work contributes to achieving the goals of precision oncology by explaining a broader spectrum of patient responses.